CClinicalTrials.gg
Sign In
CompletedNCT04127903Updated Feb 15, 2023

The Length of the Right Main Stem Bronchus as a Guide to Right-sided Double-lumen Tube Use

An interventional study of the Length of Right Main Stem Bronchus in Therapeutic Procedural Complication, sponsored by The First Hospital of Qinhuangdao. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by The First Hospital of Qinhuangdao · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The Length of the Right Main Stem Bronchus Measured by Computerised Tomography as a Guide to Right-sided Double-lumen Tube Use

Read the detailed description

The double lumen tube (DLT) is the most popular way to isolate the lungs for thoracic surgery. The variable anatomy of the length of the right main stem bronchus seems to be the main reason clinicians are unwilling to use the right-sided DLT (R-DLT). The factors that could compromise the adequate ventilation of the right lung are mostly the variable length of the Right Main Stem Bronchus and the misalignment of the lateral orifice of the right-sided DLT in regard to the right upper lobe bronchus (RULB). The objectives of this study were to validate an alternative method to estimate the length of the Right Main Stem Bronchus by Computerised Tomography as a Guide to Right-sided Double-lumen Tube Use

02

Conditions studied

  • Therapeutic Procedural Complication
03

In context

Lead sponsor

The First Hospital of Qinhuangdao is the lead sponsor of 22 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients undergoing thoracic surgery

Exclusion criteria

Exclusion Criteria:

  1. Age>70 or \<18 years
  2. ASA classifications >III
  3. BMI >35kg/m2
  4. Modified Mallampati classification ≥III
  5. Thoracic surgery within the last one month
  6. Severe cardiopulmonary disease
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    the Length of Right Main Stem Bronchus >=15mm

    Other: the Length of Right Main Stem Bronchus

  • Experimental
    the Length of Right Main Stem Bronchus <15mm

    Other: the Length of Right Main Stem Bronchus

Interventions

  • Otherthe Length of Right Main Stem Bronchus

    The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography

06

What researchers measure

Primary outcomes

  1. The incidence of Uniblocker displacement

    Time frame: 1 year

  2. The number of adjust the right-sided double-lumen tube to optimum location

    Time frame: 1 year

07

Study locations

1 site
  • The first hospital of Qinhuangdao
    Qinhuangdao, Hebei 066000, China
08

References and documents

Publications

  • Liu Z, Liu M, Zhao L, Qi X, Yu Y, Liang S, Yang X, Ma Z. Comparison of the accuracy of three methods measured the length of the right main stem bronchus by chest computed tomography as a guide to the use of right sided double-lumen tube. BMC Anesthesiol. 2022 Aug 18;22(1):264. doi: 10.1186/s12871-022-01744-z. PubMed 35982403 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04127903
Lead sponsor
The First Hospital of Qinhuangdao
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Oct 15, 2019
Primary completion
Feb 20, 2020
Completion
Apr 24, 2020
Last update
Feb 15, 2023

Study contacts

Ximing Qi
study director · The First Hospital of Qinhuangdao

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

The First Hospital of Qinhuangdao

Start the discussion